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Other names: TAL1 (SCL) interrupting locus 
Location: 1p32 
Local order: UMP-CMPK (47511608-47556531); SIL 
(47427869-47491842); TAL1 (47393984-47407363). 
Note: 47,427,869 bp from pter; End: 47,491,842 bp 




18 exons distributed over 70 kb. 5' portion of the gene 
demonstrating alternate exon utilization. 
Protein 
Description 
1287 amino acids, 148 KDa protein which is highly 
conserved in vertebrates only. No homologies to known 
protein motifs except for conserved Serin/Threonine 
phosporylation sites. 
Expression 
SIL is an immediate early gene, with ubiquitous 
expression in proliferating cells and during early 
embryonic development. SIL protein levels peak during 
mitosis and are degraded on transition to G1. SIL is 
phosphorylated in mitosis. It is expressed in multiple 
cancers. In lung cancer its expression correlates with




SIL knockout mouse embryos die in utero displaying 
holopresencephaly, randomized left/right asymmetry 
and marked apoptosis of the neural folds. Genetic 
evidence showed that SIL is required for the Sonic 
Hedgehog response pathway. SIL phosphorylation and 
interactions with PIN1 is required for maintenance of 
the mitotic checkpoint. 
Homology 
There is no homology to other known proteins. 
 
 
Genomic structure of SIL. EcoRI sites (R) are indicated. Exons are as shown; the smaller exons are not drawn to scale. 
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Schematic representation of SIL/SCL fusion mRNA. The germ line SIL (solid boxes) and SCL (open boxes) genomic structures are 
shown. The deletion breakpoints are indicated with arrows. The SIL/SCL genomic rearrangement is indicated 
below. The SIL/SCL fusion mRNA is formed by SIL exon 1 (solid box) splicing to SCL exon 3 (open box) in a head-to-tail fashion. 
 
Mutations 
Note: No mutations were found in families with 
hereditary holoprosencephaly. 
Implicated in 
SIL- TAL1 (SCL) fusion 
Note: A submicroscopic deletions fuses the promoter 
of SIL to TAL1 to induce an abnormal expression of 
TAL1. 
Disease 
T-cell ALL. This TAL1-SIL fusion transcript is found 




The promoter region of the SCL gene, a hematopoietic 
transcription factor, and the coding region of the SIL 
gene are deleted. The molecular result of this SIL/SCL 
rearrangement is an interstitial deletion on chromosome 
1 that juxtaposes the 5' portion of the SIL gene to the 
coding region of the SCL gene. A SIL/SCL fusion 
mRNA is produced, with SIL exon 1 splicing to SCL 
exon 3 in a head-to-tail fashion. Because these are both 
5' untranslated region (UTR) exons, the net result is 
that SIL promoter and enhancer elements drive the 
expression of a full length SCL gene product. 
SIL overexpression in lung cancer 
Note: SIL is also overexpressed in various solid tumors 
(melanoma, lymphoma, ovary cancer, breast cancer 
colon cancer lung and prostate cancer) and leukemic 
cell lines (Dami-acute megakaryocytic, and K562- 
erythroid blast crisis of chronic myeloid leukemia). 
Disease 
High expression in non-small cell lung cancer 
(NSCLC). In addition, high expression levels in lung 
adenocarcinoma, lung squamous carcinoma and lung 
small cell carcinoma. 
Prognosis 
SIL expression is associated with cell proliferation. In 
lung cancer, SIL overexpression is correlated with h gh 
mitotic activity. 
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